Priority Lists
Protocol Posting of
Activations
Activation
Protocol for Assessment of Capecitabine for Advanced Colorectal Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger than 60 Years)
| Study Coordinator(s) | Heinz- Josef Lenz, M.D., Derek Raghavan, M.D.,Ph.D., Carolyn C. Gotay, Ph.D., Dorothy Coleman, R.N., M.S. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, Who Have The Ability To Perform Outpatient Blood Collections For Pharmacology Studies |
Closures
PERMANENT CLOSURE
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Cancer.
| Study Coordinator(s) | Joseph W. Basler, Ph.D., M.D |
| Participants | UCOP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, NCORP, Members |
| Closure Date | 2003-02-15 |
Partial Closure
Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or with Performance Status 2
| Study Coordinator(s) | Paul J. Hesketh, M.D., Derick H.M. Lau, M.D.,Ph.D., James H. Doroshow, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
| Closure Date | 2003-07-01 |
Permanent Closure
Phase II Trial of Gemcitabine and Irinotecan in Patients with Untreated Extensive Stage Small Cell Lung Cancer (SCLC)
| Study Coordinator(s) | Wallace L. Akerley, M.D., Paul J. Hesketh, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
| Closure Date | 2003-02-15 |
Partial Closure
Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
| Study Coordinator(s) | Howard (Jack) West, M.D., Ralph B. Vance, M.D., Wilbur A. Franklin, M.D., Derick H.M. Lau, M.D.,Ph.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
| Closure Date | 2003-07-01 |
Amendments, Revisions, Memoranda
Amendment #1
Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study
| Study Coordinator(s) | Kim A. Margolin, M.D. |
| Participants | Limited Institutions: BMT Members |
Revision #1
Phase III Randomized Study of Four Weeks of High Dose IFN-alpha2b in Stage T2b N0, T3a-b N0, T4a-b N0, and T1-4, N1a, 2a, 3(Microscopic) Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D. |
| Participants | CTSU |
Amendment #4
Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors
| Study Coordinator(s) | Richard I. Fisher, M.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Pathologists, NCORP |
Revision #1
Phase III Randomized Trial of Fludarabine and Cyclophosphamide versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia.
| Study Coordinator(s) | Mohamad A. Hussein, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Amendment #1
A Phase II Trial of Preradiation in Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma
| Study Coordinator(s) | Geoffrey R. Barger, M.D. |
| Participants | Members, Medical Oncologists, NCORP |
Revision #2
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" after Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
| Action Codes | IP, AC, ER |
| Study Coordinator(s) | Kim A. Margolin, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Revision #1
Phase III Trial of Orchiectomy/LHRH Analog + Flutamide + Suramin + Hydrocortisone vs. Orchiectomy/LHRH Analog + Flutamide in Patients with Metastatic Prostate Cancer
| Study Coordinator(s) | A. Oliver Sartor, M.D. |
Amendment #3
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
Amendment #3
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients with Advanced Colorectal Carcinoma Previously Treated with 5-FU
| Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D. |
| Participants | Members, Surgeons, NCORP |
Memorandum
A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-Cell Acute Lymphoblastic Leukemia (ALL)
| Study Coordinator(s) | Steven E. Coutre, M.D., David R. Head, M.D., David H. Boldt, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Memorandum
Evaluation of Interferon Alpha-2b and Thalidomide in Patients with Disseminated Malignant Melanoma, Phase II
| Study Coordinator(s) | Laura F. Hutchins, M.D., Joseph I. Clark, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #9
Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or with Performance Status 2
| Study Coordinator(s) | Paul J. Hesketh, M.D., Derick H.M. Lau, M.D.,Ph.D., James H. Doroshow, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #9
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
| Study Coordinator(s) | Robert P. Whitehead, M.D. |
| Participants | Members, NCORP |
Memorandum
Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
| Study Coordinator(s) | Alison T. Stopeck, M.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D., William T. Bellamy, R. Ph. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Amendment #2
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer
| Study Coordinator(s) | Maha H.A. Hussain, M.D., Primo N. Lara, Jr., M.D., Wael A. Sakr, M.D., Michael A. Tainsky, Ph.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists |
Revision #3
A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasma Proliferative Disorders
| Action Codes | ER |
| Study Coordinator(s) | Madhav V. Dhodapkar, M.D., Bart Barlogie, M.D.,Ph.D., John D. Shaughnessy, Jr., Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #1
Phase II Trial of Patients with Limited Stage Small Cell Lung Cancer Treated with Thoracic Radiation Therapy and Chemotherapy with Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines
| Study Coordinator(s) | Abdul-Rahman Jazieh, M.D., Wallace L. Akerley, M.D., Laurie E. Gaspar, M.D., Mary L. Disis, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Amendment #2
Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
| Study Coordinator(s) | Howard (Jack) West, M.D., Ralph B. Vance, M.D., Wilbur A. Franklin, M.D., Derick H.M. Lau, M.D.,Ph.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Revision #5
Phase II Trial of Chronic Oral ZD1839 (Iressa) in Both Previously-Untreated and Previously-Treated Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
| Study Coordinator(s) | Howard (Jack) West, M.D., Ralph B. Vance, M.D., Wilbur A. Franklin, M.D., Derick H.M. Lau, M.D.,Ph.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Memorandum
A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma after Failure of Initial Platinum-Based Chemotherapy
| Study Coordinator(s) | Ana Maria Lopez, M.D., M.Ph, Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, CTSU Institutions in the United States |
Memorandum
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma
| Study Coordinator(s) | Mohamad A. Hussein, M.D., James K. Weick, M.D. |
| Participants | NCORP, Members |
Memorandum
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III
| Study Coordinator(s) | Lori J. Pierce, M.D. |
| Participants | Medical Oncologists, Radiation Oncologists, Surgeons, NCCTG, RTOG, ACOSOG, ECOG, CALGB, NCORP, Members, NCIC-CTG, NSABP |
Memorandum
Intergroup Rectal Adjuvant Protocol, A Phase III Study
| Study Coordinator(s) | Stephen R. Smalley, M.D., John S. Macdonald, M.D. |
Memorandum
Conservative Treatment of Adenocarcinoma of the Distal Rectum: Local Resection Plus Adjuvant 5-FU/Radiation Therapy, A Phase II Intergroup Study
| Study Coordinator(s) | Maha H.A. Hussain, M.D., Kenneth J. Russell, M.D., Mika N. Sinanan, M.D.,Ph.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required